GlassScriptPhysician profile
Grant D Sievertsen
NPI 1134197619
$598.97
in general payments reported to CMS, 2019-2025
11 companies · $203 in 2025
The $203 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.69 · 2020: $152 · 2021: $11.82 · 2022: $26.78 · 2023: $43.49 · 2024: $135 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $381.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $202.27 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Exact Sciences Corporation | $99.19 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $72.33 | 2024-2025 | |
| Lilly USA, LLC | $46.20 | 2024-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $41.68 | 2023-2025 | Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $38.79 | 2024-2025 | Airsupra |
| Sanofi-Aventis U.S. LLC | $26.69 | 2019 | |
| Abbvie INC. | $26.38 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.66 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $14.26 | 2022 | |
| Xeris Pharmaceuticals, INC. | $12.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grant Sievertsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.